Latest News and Press Releases

IntoCell and Xcellon Biologics partner to expand ADC development access, combining IntoCell's OHPAS payload-linker platform with Xcellon's CDMO expertise.

ICP-B794 has demonstrated superior anti-tumor activity in animal models, and exhibited significant tumor-killing effects even in large tumors.

Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cellsAdvancing AT-01, a first-in-class...

Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques. Le tour de table est...

Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led by Bpifrance with co-leads Kurma Partners, Andera...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement...

TAIPEI, Taiwan, Sept. 02, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-902, an antibody-drug...

FDA grants Orphan Drug Designation to Medicovestor’s ADoBind MC001, a novel ADC targeting hard-to-treat pancreatic cancer.

Medicovestor and Sanyou team up to develop first-in-class chemoimmunotherapy ADCs, combining AI antibody tech with novel dual-targeting platforms.